Healthcare Stocks: Red Flags in Myriad, Enovis, Henry Schein
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Healthcare stocks have outperformed the S&P 500, driven by new drugs and telehealth. However, regulations can cause sudden drops. Were examining three underperforming names: Myriad Genetics, Enovis, and Henry Schein. Myriad Genetics, a genetic testing pioneer, has low revenue growth and negative capital returns. Enovis, an orthopedic device maker, has seen sales decline and negative capital returns. Henry Schein, a global medical and dental equipment distributor, has stagnant revenue and shrinking returns. These companies underscore the importance of thorough due diligence in healthcare investments.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/60c568da22886ab5